<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<?properties open_access?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">Acta Naturae</journal-id>
<journal-id journal-id-type="iso-abbrev">Acta Naturae</journal-id>
<journal-id journal-id-type="publisher-id">ActaNaturae</journal-id>
<journal-title-group>
<journal-title>Acta Naturae</journal-title>
</journal-title-group>
<issn pub-type="ppub">2075-8251</issn>
<publisher>
<publisher-name>A.I. Gordeyev</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">27437140</article-id>
<article-id pub-id-type="pmc">4947989</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Research Article</subject>
<subj-group>
<subject>Molecular Biology</subject>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>Monogenec Arrhythmic Syndromes: From Molecular and Genetic Aspects to Bedside</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>E.Z.</surname>
<given-names>Golukhova</given-names>
</name>
<xref ref-type="aff" rid="AF1"></xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>O.I.</surname>
<given-names>Gromova</given-names>
</name>
<email>gromova3112@gmail.com</email>
<xref ref-type="aff" rid="AF1"></xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>R.A.</surname>
<given-names>Shomahov</given-names>
</name>
<xref ref-type="aff" rid="AF1"></xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>N.I.</surname>
<given-names>Bulaeva</given-names>
</name>
<xref ref-type="aff" rid="AF1"></xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>L.A.</surname>
<given-names>Bockeria</given-names>
</name>
<xref ref-type="aff" rid="AF1"></xref>
</contrib>
</contrib-group>
<aff id="AF1">Bakoulev Centre for Cardiovascular Surgery, Rublevskoye sh. 135, 121552, Moscow, Russia</aff>
<pub-date pub-type="ppub">
<season>Apr-Jun</season>
<year>2016</year>
</pub-date>
<volume>8</volume>
<issue>2</issue>
<fpage>62</fpage>
<lpage>74</lpage>
<history>
<date date-type="received">
<day>17</day>
<month>10</month>
<year>2015</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright ® 2016 Park-media Ltd.</copyright-statement>
<copyright-year>2016</copyright-year>
<license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.0/">
<license-p>
This is an open-access article distributed under the terms of the
Creative Commons Attribution License, which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is
properly cited.
</license-p>
</license>
</permissions>
<abstract>
<p>
The abrupt cessation of effective cardiac function that is generally due to
heart rhythm disorders can cause sudden and unexpected death at any age and is
referred to as a syndrome called “sudden cardiac death” (SCD).
Annually, about 400,000 cases of SCD occur in the United States alone. Less
than 5% of the resuscitation techniques are effective. The prevalence of SCD in
a population rises with age according to the prevalence of coronary artery
disease, which is the most common cause of sudden cardiac arrest. However,
there is a peak in SCD incidence for the age below 5 years, which is equal to
17 cases per 100,000 of the population. This peak is due to congenital
monogenic arrhythmic canalopathies. Despite their relative rarity, these cases
are obviously the most tragic. The immediate causes, or mechanisms, of SCD are
comprehensive. Generally, it is arrhythmic death due to ventricular
tachyarrythmias – sustained ventricular tachycardia (VT) or ventricular
fibrillation (VF). Bradyarrhythmias and pulseless electrical activity account
for no more than 40% of all registered cardiac arrests, and they are more often
the outcome of the abovementioned arrhythmias. Our current understanding of the
mechanisms responsible for SCD has emerged from decades of basic science
investigation into the normal electrophysiology of the heart, the molecular
physiology of cardiac ion channels, the fundamental cellular and tissue events
associated with cardiac arrhythmias, and the molecular genetics of monogenic
disorders of the heart rhythm (for example, the long QT syndrome). This review
presents an overview of the molecular and genetic basis of SCD in the long QT
syndrome, Brugada syndrome, short QT syndrome, catecholaminergic polymorphic
ventricular tachycardia and idiopathic ventricular fibrillation, and
arrhythmogenic right ventricular dysplasia, and sudden cardiac death
prevention strategies by modern techniques (including implantable
cardioverter-defibrillator)
</p>
</abstract>
<kwd-group kwd-group-type="author">
<kwd>sudden cardiac death</kwd>
<kwd>monogenic canalopathy</kwd>
<kwd>long QT syndrome</kwd>
<kwd>Brugada syndrome</kwd>
<kwd>arrhythmic right ventricular dysplasia</kwd>
<kwd>implantable cardioverter-defibrillator</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec>
<title>INTRODUCTION</title>
<p>
The term “sudden cardiac death” (SCD) is used to denote death,
presumably from cardiac causes, which occurs within 1 h after the onset of
acute symptoms [<xref ref-type="bibr" rid="R1">1</xref>]. As a rule, the direct
cause of such an outcome is cardiac arrhythmias: ventricular tachycardia (VT)
and ventricular fibrillation (VF), which disrupt the pumping function of the
heart leading to acute circulatory disorders and, in sufficient duration, to
irreversible consequences with a fatal outcome. According to U.S. registers,
the annual incidence of SCD in the United States is 50–00 per 100,000 of
the population [<xref ref-type="bibr" rid="R2">2</xref>], or ca.
350–00,000 cases per year [<xref ref-type="bibr" rid="R3">3</xref>]. In
Russia, 200–50,000 cases of SCD are registered each year [<xref ref-type="bibr" rid="R4">4</xref>].
</p>
<p>
The majority of SCD cases (75–80%) occur in adults and is associated with
coronary artery disease (CAD). The period of acute myocardial infarction is the
most susceptible to the development of ventricular arrhythmias. According to
population studies, the incidence of SCD increases with age proportionally to
the increase in CAD prevalence. For example, at the age below 35 years, the
incidence of SCD is minimal (up to six cases per 100,000), and it gradually
increases in middle and older age groups and reaches its maximum (346 cases per
100,000) for people aged 75 to 84 years. However, there is an additional peak
in SCD incidence in children under the age of 5 (17 per 100,000), which is due
to familial arrhythmogenic canalopathies [<xref ref-type="bibr" rid="R5">5</xref>].
</p>
<p>
The second most common cause of SCD is cardiomyopathies: hypertrophic
cardiomyopathy and nonischemic dilated cardiomyopathy, which accounts for about
10–15% of all sudden arrhythmic deaths [<xref ref-type="bibr" rid="R6">6</xref>]. Infiltrative, inflammatory, and valvular heart diseases of
different etiologies account for the majority of the remaining causes. Children
and young adults are also susceptible to SCD usually due to genetic diseases,
socalled canalopathies, which represent only a small portion of SCD causes (no
more than 1–2%) [<xref ref-type="bibr" rid="R6">6</xref>].
</p>
<p>
Despite the different etiologies of sudden death, the causes behind this event
are universal. As has already been mentioned, most commonly cardiac arrest is
caused by sustained VT or VF. Primary pulseless electrical activity (PEA) or
bradyarrhythmias is less common, accounting for no more than 40% of all SCD
cases [<xref ref-type="bibr" rid="R5">5</xref>], and more often the two are
outcomes of ventricular tachyarrhythmias. VT and/or VF hold the greatest
potential for reversibility; only during this short period, until the
transition to PEA or asystole, can normal heart rhythm be restored by
electrical defibrillation. The need to capitalize on this “therapeutic
window” dictates the need for the fastest possible diagnosis and
immediate defibrillation.
</p>
<p>
The widespread use of implantable cardioverter-defibrillators (ICD) for both
primary and secondary prevention of SCD has significantly reduced mortality in
high-risk patients. Nevertheless, the incidence of SCD remains high. Even now,
in an era of high-speed and new methods of information transfer, the survival
rate after resuscitation does not exceed 5% in developed countries [<xref ref-type="bibr" rid="R6">6</xref>].
</p>
<p>
This review is dedicated to the rarest congenital causes of sudden death:
monogenic arrhythmic disorders, as well as arrhythmogenic right ventricular
dysplasia and modern approaches to sudden death risk stratification in these
patients.
</p>
</sec>
<sec>
<title>CELLULAR BASIS OF ELECTROPHYSIOLOGY</title>
<p>
The physiological processes of formation and propagation of electrical impulses
in the heart muscle, as well as the “excitation-contraction”
process, are remarkably fine-tuned and occur under the influence of harmonious
workings of ion channels in accord with a variety of regulatory bioactive
substances. Ion channels are proteins that enable selective permeability of the
cell membrane for a particular ion. Voltage-gated ion channels open and close
under the influence of the membrane potential, and ligand-gated ion channels
require binding to an intra- or extracellular molecule to open an ion pore. In
addition to ion channels, the intracellular homeostasis of ions is also
maintained by ion pumps and exchangers that enable transmembrane transport of
only certain ions with (pumps) or without (exchangers) use of ATP energy
resources.
</p>
<p>
The cardiomyocyte’s action potential is initiated by a regional change in
the membrane potential that activates voltage-gated sodium (Na<sup>+</sup>)
channels and initiate a fast but transient sodium current
(<italic>I</italic><sub>Na</sub>) that produces the typical ascending slope of
the action potential curve known as Phase 0 depolarization
(<italic><xref ref-type="fig" rid="F1">Fig. 1</xref></italic>).
Fast Phase 1 early repolarization is due to several ionic
currents: the transient potassium current (K<sup>+</sup>),
<italic>I</italic>to1 (transient outward), and the calcium-activated chloride
current (Cl<sup>-</sup>),<italic> I</italic><sub>to</sub>2 [<xref ref-type="bibr" rid="R7">7</xref>]. During Phases 0 and 1,
Na<sup>+</sup>-channels are rapidly inactivated, whereas voltage-gated calcium
(Ca<sup><sup>2+</sup></sup>) channels (L-type) are activated and participate in
the formation of the sustained plateau of membrane depolarization. The plateau
phase (Phase 2) is sustained by a delicate balance between the inward
Ca<sup>2+</sup> current (<italic>I</italic><sub>Ca</sub>) through L-type
channels, with the small residual Na current (<italic>I</italic><sub>Na</sub>)
and the emerging outflow K<sup>+</sup> current. The activation of
K<sup>+</sup>-channels, together with inactivation of Ca<sup>2+</sup> channels,
shifts this balance towards the outward currents, thereby initiating Phase 3
repolarization.
</p>
<fig id="F1" orientation="portrait" position="float">
<label>Fig. 1</label>
<caption>
<p>
Approximate temporal
relationships between
surface ECG (A) and typical
ventricular action potential
(B) and ionic currents (C)
through the membrane of
cardiomyocyte. 0 – depolarization
phase: 1 – rapid
repolarization phase;
2 – plateau; 3 – repolarization;
4 – resting phase
</p>
</caption>
<graphic xlink:href="AN20758251-29-062-g001"></graphic>
</fig>
<p>
The outward potassium current (the so-called delayed rectifier current)
consists of at least three components: ultra-rapid
(<italic>I</italic><sub>Kur</sub>), rapid (<italic>I</italic><sub>Kr</sub>),
and slow (<italic>I</italic><sub>Ks</sub>), which differ in the rate of
activation and pharmacological sensitivity [<xref ref-type="bibr" rid="R7">7</xref>]. These differences define the unequal duration of the action
potential in different portions of the myocardium based on the level of channel
expression [<xref ref-type="bibr" rid="R8">8</xref>]. The expression of genes
encoding subunits of rapid K<sup>+</sup>-channels
(<italic>I</italic><sub>Kr</sub> current), <italic>KCNH2</italic>, is subject
to pronounced diurnal variation, playing the role of a “molecular
clock” of sort. Disruptions of the circadian clock mechanism may be
associated with an increased risk of sudden death [<xref ref-type="bibr" rid="R9">9</xref>].
</p>
<p>
Finally, an abnormal inward rectifier current (<italic>I</italic><sub>K</sub>1)
completes the process of cardiomyocyte membrane repolarization. This current is
called abnormal because its formative K<sup>+</sup>-channels are activated only
in the case of negative charge of the membrane potential and enable, primarily,
an inward current.
</p>
<p>
Pacemaker myocardial cells
(<italic><xref ref-type="fig" rid="F2">Fig. 2</xref></italic>) possess a special
mechanism for the action potential buildup, which can spontaneously generate
the action potential. Even the cardiomyocytes of the sino-atrial node that are
isolated from all surrounding tissues maintain spontaneous diastolic
depolarization. [<xref ref-type="bibr" rid="R7">7</xref>]. This ability is
enabled through a special ion flow, called “funny”
–<italic>I</italic><sub>f</sub> –due to its unusual properties. The
<italic>I</italic><sub>f</sub> current is a mixed inward calcium-sodium current
which is gradually initiated during the hyperpolarization (after the completion
of Phase 4 repolarization) at a transmembrane potential of –40/–50
mV and is fully activated at a potential of about –100 mV, initiating the
action potential. The pacemaker current is implemented through a family of ion
channels discovered in the 1990s and called HCN channels
(hyperpolarization-activated channels). The autonomic modulation of the
pacemaker current has undeniable significance for normal physiology of cardiac
activity and is implemented through cAMP. There are four isoforms of
HCN-channels which differ in the rate of activation and inactivation, as well
as in sensitivity to cAMP. Experiments have shown that adrenergic and
cholinergic neurotransmitters cause an increase or decrease in the level of
intracellular cAMP, respectively. Subsequently, cAMP binds directly to the
HCN-channel, strengthening or weakening the <italic>I</italic>f current,
resulting in acceleration or deceleration of spontaneous depolarization.
</p>
<fig id="F2" orientation="portrait" position="float">
<label>Fig. 2</label>
<caption>
<p>
Action potential of pacemaker cell. 1 – automatic
depolarization – I<sub>f</sub> channels are open; 2 – membrane
potential reaches the threshold level – transient T-type
calcium channels are opening; 3 – slow (L-type) calcium
channels are opening – depolarization; 4 – L-type calcium
channels are closing, potassium channels are opening –
hyperpolarization
</p>
</caption>
<graphic xlink:href="AN20758251-29-062-g002"></graphic>
</fig>
<p>
Ion exchangers and pumps play a crucial role in the disposal of the excess of
ions arising during the formation of each action potential, as well as in the
maintenance of exact levels of ions within the cell. The two most studied ion
pumps are the membranes Na<sup>+</sup>-K<sup>+</sup>-ATPase and
Ca<sup>2+</sup>-ATP-ase and the two most studied ion exchangers are the
membranes Na<sup>+</sup>-Ca<sup>2+</sup> and Na<sup>+</sup>-H<sup>+</sup>.
</p>
<p>
Na<sup>+</sup>-K<sup>+</sup>-ATP-ase is a magnesium-activated (Mg<sup>2+</sup>)
cardiomyocyte membrane enzyme. Under physiological conditions, the pump
maintains a normal resting potential, ensuring the transfer of three
Na<sup>+</sup> ions out of the cell in exchange for the influx of two
K<sup>+</sup> ions into the cell. The function of the Na<sup>+</sup>-pump is
critical in maintaining the level of intracellular Na<sup>+</sup>, and,
consequently, it affects cardiomyocyte contractility and excitability [<xref ref-type="bibr" rid="R7">7</xref>].
</p>
<p>
The membrane Ca<sup>2+</sup> pump (ATPase), together with the
Na<sup>+</sup>-Ca<sup>2+</sup> exchanger, removes intracellular
Ca<sup>2+</sup>. However, its role in the utilization of Ca<sup>2+</sup> is
presumably small. Ca<sup>2+</sup>-ATP-ase of the sarcoplasmic reticulum is much
more important. The primary role in removing excess intracellular
Ca<sup>2+</sup> belongs to the Na<sup>+</sup>-Ca<sup>2+</sup> exchanger.
Switching-off of the gene encoding the sarcolemmal protein leads to the death
of an embryo on Days 9–10 after conception [<xref ref-type="bibr" rid="R7">7</xref>]. The Na<sup>+</sup>-Ca<sup>2+</sup> exchanger is a
quantitative transfer protein providing transport of Na+ in exchange for
Ca<sup>2+</sup> (3:1). However, the function of the
Na<sup>+</sup>-Ca<sup>2+</sup> exchanger is coordinated with the ever- changing
inward flow of Ca<sup>2+</sup>: the system removes the exact amount of
Ca<sup>2+</sup> that has entered into the cell during the ongoing cardiac
cycle. Two systems – the Na<sup>+</sup>-Ca<sup>2+</sup> exchanger and the
sarcoplasmic reticulum (SPR) – participate in the removal of
Ca<sup>2+</sup> from the cytoplasm during the relaxation of the myocardium.
Experiments have proven that each system alone is able to fully enable
myocardial relaxation. Ca<sup>2+</sup>-ATP-ase of the sarcoplasmic reticulum
can ensure rapid relaxation of the heart muscle, but it is unable to work on
its own over several consecutive contractions. In contrast, the
Na<sup>+</sup>-Ca<sup>2+</sup> exchanger enables repeated outflow of
Ca<sup>2+</sup> from one contraction to another. Depending on the
electrochemical gradients, the Na+-Ca<sup>2+</sup> exchanger is able to provide
not only the outflow of Ca<sup>2+</sup>, but also the inward Ca<sup>2+</sup>
current in the cell to maintain or enhance myocardial contractility.
</p>
<p>
The Na<sup>+</sup>-H<sup>+</sup>-exchanger is also a quantitative transfer
protein; it replaces one intracellular proton with one extracellular sodium ion
and plays an essential role in the maintenance of intracellular pH.
</p>
<p>
Ion channels function is regulated by a variety of intra- and extracardiac
factors, the most significant of which is β-adrenergic stimulation. For
example, upon physiological activation of the sympathetic nervous system due to
physical exertion or emotional stress, known in English literature as
“fight or flight” reaction, the increased heart rate requires
immediate shortening of the cardiomyocytes action potential, which is
implemented through an increase of <italic>I</italic><sub>Ks</sub> via
β-adrenergic stimulation [<xref ref-type="bibr" rid="R7">7</xref>]. In
addition, the sympathetic stimulation enhances myocardial contractility, mainly
through an increase in the inward Ca<sup>2+</sup> current and increased
accumulation of Ca<sup>2+</sup> in the sarcoplasmic reticulum, for subsequent
enhanced release inside the cell.
</p>
<p>
Intracellular Ca<sup>2+</sup> homeostasis mainly depends on normal operation of
the SPR. Voltage-gated Ca<sup>2+</sup>-channels in the SPR membrane are
regulated by the socalled ryanodine receptors, RyR2, whose dysfunction can lead
to cell overload with Ca<sup>2+</sup> and subsequent increase in triggering of
myocardial activity.
</p>
</sec>
<sec>
<title>MONOGENIC CAUSES OF SUDDEN CARDIAC DEATH</title>
<p>
The symphony of ion channel performance is disturbed by genetically
predetermined ion canalopathies. Such defects can trigger fatal arrhythmias,
which usually occur in childhood or at a young age. Despite a low incidence,
these diseases can be identified by molecular diagnostics, which have allowed
to elucidate the most frequent causes of these genetic abnormalities over
almost two decades. Currently, more than 25 genes are known whose disruption of
expression can cause susceptibility to ventricular tachyarrhythmias. Only few
isolated nosological forms are identified clinically. The main ones are long QT
syndrome (LQTS), short QT syndrome (SQTS), Brugada syndrome (BS),
catecholaminergic polymorphic ventricular tachycardia (CPVT), and idiopathic
VF. These diseases are based on three pathophysiological mechanisms: impaired
repolarization (LQTS, SQTS, Brugada syndrome), delayed ventricular conduction
(Brugada syndrome), and disruption of intracellular Ca<sup>2+</sup> homeostasis
(CPVT).
</p>
<p>
<bold>Congenital long QT syndrome (LQTS)</bold>
</p>
<p>
The most common variant of LQTS occurs in the Romano- Ward syndrome, which is
inherited through an autosomal dominant mechanism (incidence of about 1 in
2,500 live births) [<xref ref-type="bibr" rid="R10">10</xref>]. A less frequent
variant is the Jervell-Lange-Nielsen syndrome, which is autosomal- recessive
and combined with deafness. Genetically, LQTS is very heterogeneous; there are
at least 8 identified variants. The most common genetic subtype is LQTS1, which
is caused by mutations in the <italic>KCNQ1</italic> gene that encodes a
subunit of the voltage-gated K<sup>+</sup> channel responsible for the slow
outward K<sup>+</sup> current (<italic>I</italic><sub>Ks</sub>). Mutations in
the <italic>KCNH2 </italic>gene that defines the structure of another version
of the K<sup>+</sup> channel subunit responsible for a rapid outward
K<sup>+</sup> current (<italic>I</italic>Kr) result in the development of the
second major subtype, LQTS2. Heterozygous mutations in <italic>KCNQ1
</italic>and<italic> KCNH2 </italic>cause a loss of function by the respective
channels, decreasing <italic>I</italic><sub>Ks</sub> or
<italic>I</italic><sub>Kr</sub>, respectively, which slows down the
repolarization and prolong the ventricular action potential. An increased heart
rate during sympathetic activation reveals the inability of the cardiomyocytes
in such people to increase <italic>I</italic><sub>Ks</sub>. It explains the
fact that exercise and emotional stress provoke the onset of life-threatening
arrhythmias in patients with LQTS1. At the same time, trigger factors for
patients with LQTS2 are sharp acoustic stimuli (cry, alarm clock, etc.) [<xref ref-type="bibr" rid="R11">11</xref>]. The genetic specificity of arrhythmogenic
triggers has been demonstrated in a sample of 700 patients with a known LQTS
genotype. For example, 99% of arrhythmic events during swimming occurred in
patients with LQTS1, whereas 80% of the events provoked by sudden sounds
occurred in patients with LQTS2 [<xref ref-type="bibr" rid="R12">12</xref>].
</p>
<p>
Ca. 10% of all LQTS are caused by mutations in the<italic> SCN5A </italic>gene
(LQTS3), which encodes the α-subunit of the Na<sup>+</sup>-channel, which
enables a rapid inward Na<sup>+</sup> current during Phase 0 depolarization.
Typically, these are gains of function mutations that disrupt channel
inactivation and increase in a constant <italic>I</italic><sub>Na</sub> [<xref ref-type="bibr" rid="R13">13</xref>]. A similar phenotype has been observed for
the mutations in other genes (including <italic>CAV3</italic>, <italic>SCN4B,
</italic>and <italic>SNTA1</italic>) which encode proteins that directly or
indirectly affect sodium channels. A constantly elevated Na<sup>+</sup> current
disrupts the physiological balance between inward and outward ions flows during
the plateau phase, causing delayed repolarization, prolongation of the action
potential, and predisposition to re-entry arrhythmias. Selective blockade of
the constant Na<sup>+</sup> current by some antiarrhythmic drugs (such as
mexiletine) or the antianginal drug ranolazine may serve as a
pathophysiologically based approach to LQTS3 treatment [<xref ref-type="bibr" rid="R14">14</xref>, <xref ref-type="bibr" rid="R15">15</xref>]. It should be
noted that the <italic>KCNQ1</italic>, <italic>KCNH2, </italic>and
<italic>SCN5A</italic> genes, mutations in which cause LQTS 1, 2 and 3,
respectively, are so-called “major” LQTS genes, and mutations in
them imply a high probability of congenital LQTS and is important for risk
stratification (see below).
</p>
<p>
Acquired LQTS are more common than congenital ones, and they have very similar
pathophysiological mechanisms. The most common variant of acquired LQTS is
medical prolongation of the QT interval that occurs when cardiac or noncardiac
medications are used to block the K<sup>+</sup> channels that enable<italic>
I</italic><sub>Kr</sub> (HERG-channel), which leads to a slowing-down of
ventricular repolarization. There are also variants of genetic predisposition
to drug-related prolongation of the QT interval [<xref ref-type="bibr" rid="R16">16</xref>]. These conditions are associated with partial loss of
function in respect to <italic>I</italic><sub>Ks</sub>, which leads to a
decrease in the so-called repolarization reserve that can manifest itself in
the case of <italic>I</italic><sub>Kr</sub> inhibition with drugs. There are
also individual cases of manifestation of latent congenital LQTS in patients
receiving drugs that block HERG-channels (e.g., antiarrhythmic drugs such as
amiodarone, sotalol, dofetilide, propafenone) [<xref ref-type="bibr" rid="R13">13</xref>], or in case of other pathological conditions, such as
myocardial infarction [<xref ref-type="bibr" rid="R17">17</xref>].
</p>
<p>
In addition to the Jervell-Lange-Nielsen syndrome, there are two other types of
LQTS with extracardiac manifestations. The Andersen syndrome is an autosomal
dominant disease characterized by ventricular arrhythmias, periodic paralysis,
and bone manifestations [<xref ref-type="bibr" rid="R12">12</xref>]. Anderson
syndrome is phenotypically heterogeneous, often with one or two clinical signs.
Although ventricular arrhythmias can be classified as major manifestations of
the disease, they rarely result in sudden death [<xref ref-type="bibr" rid="R13">13</xref>]. Andersen syndrome is associated with a mutation in the
<italic>KCNJ2 </italic>gene that encodes the K<sup>+</sup>-channel which
enables an abnormal inward rectifier current,<italic> I</italic><sub>K1</sub>,
an important component of Phase 3 repolarization. Disruption of the channel
function leads to a lengthening of the action potential and increased tendency
towards re-entry.
</p>
<p>
The Timothy syndrome is associated with a mutation in the <italic>CACNA1C
</italic>gene that encodes the subunit of the voltage-gated Ca<sup>2+</sup>
channel. Symptoms of Timothy syndrome include heart rhythm abnormalities,
syndactyly, and autism [<xref ref-type="bibr" rid="R13">13</xref>]. The
mutation causes pronounced disruption of Ca<sup>2+</sup> channel inactivation
and an excessive Ca<sup>2+</sup> current during the plateau phase.
</p>
<fig id="F3" orientation="portrait" position="float">
<label>Fig. 3</label>
<caption>
<p>
Fragment of ECG Holter monitoring of a patient,
female, 13 y.o., diagnosis congenital long QT syndrome.
Paroxysm of torsades de pointes (own data).
</p>
</caption>
<graphic xlink:href="AN20758251-29-062-g003"></graphic>
</fig>
<p>
LQTS is characterized by a particular electrocardiographic pattern immediately
prior to the ventricular tachycardia, the so-called short-long-short sequence
(SLS) or “cascade” phenomenon, which includes alternation of
shortening of RR intervals due to supraventricular premature contraction
(short), followed by post-premature contraction pause (long) and repeated
ventricular premature contraction (short), with subsequent “torsades de
pointes” tachycardia (<italic><xref ref-type="fig" rid="F3">Fig. 3</xref></italic>)
[<xref ref-type="bibr" rid="R12">12</xref>, <xref ref-type="bibr" rid="R18">18</xref>].
In 2011, P. Schwartz presented updated diagnostic criteria for LQTS
(<italic><xref ref-type="table" rid="T1">Table 1</xref></italic>).
A total score of ≥3.5 justifies a LQTS diagnosis (in the absence of secondary causes)
[<xref ref-type="bibr" rid="R19">19</xref>-<xref ref-type="bibr" rid="R21">21</xref>].
Furthermore, a LQTS diagnosis can be established by identifying tcharacteristic genetic
mutation, regardless of the duration of the QT interval [<xref ref-type="bibr" rid="R21">21</xref>].
</p>
<table-wrap id="T1" orientation="portrait" position="float">
<label>Table 1</label>
<caption>
<p>
Diagnostic criteria for long QT syndrome.
P. Schwartz score (2011) [<xref ref-type="bibr" rid="R19">19</xref>]
</p>
</caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th colspan="1" rowspan="1">Criteria</th>
<th colspan="1" rowspan="1">Points</th>
</tr>
</thead>
<tbody>
<tr>
<td align="center" colspan="1" rowspan="1">QTc &gt; 480 ms</td>
<td align="center" colspan="1" rowspan="1">3</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1">QTc = 460–470 msc</td>
<td align="center" colspan="1" rowspan="1">2</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1">QTc = 450 ms (men)</td>
<td align="center" colspan="1" rowspan="1">1</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1">
QTc 4th minute of recovery from exercise stress
test ≥ 480 ms
</td>
<td align="center" colspan="1" rowspan="1">1</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1">Torsades-de-Pointes</td>
<td align="center" colspan="1" rowspan="1">2</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1">T-wave alternans</td>
<td align="center" colspan="1" rowspan="1">1</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1">Notched T wave in 3 leads</td>
<td align="center" colspan="1" rowspan="1">1</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1">Low heart rate for age</td>
<td align="center" colspan="1" rowspan="1">0.5</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1">Stress-induced syncope</td>
<td align="center" colspan="1" rowspan="1">2</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1">Stress-free syncope</td>
<td align="center" colspan="1" rowspan="1">1</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1">Congenital deafness</td>
<td align="center" colspan="1" rowspan="1">0.5</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1">Family members with definite LQTS</td>
<td align="center" colspan="1" rowspan="1">1</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1">
Unexplained sudden cardiac death younger than<break></break>
age 30 among immediate family members
</td>
<td align="center" colspan="1" rowspan="1">0.5</td>
</tr>
</tbody>
</table>
</table-wrap>
<p>
Both the genetic status and clinical data are important for a stratification of
the risk of arrhythmic events in patients with LQTS. Researchers at the Mayo
Clinic Giudicessi J.R. <italic>et al</italic>. [<xref ref-type="bibr" rid="R22">22</xref>]
have developed a risk stratification scheme for primary
and recurrent cardiac events, including syncope, sudden cardiac arrest or
sudden cardiac death before the age of 40 years, based on recent studies that
examined adverse events in LQTS patients
(<italic><xref ref-type="fig" rid="F4">Fig. 4</xref></italic>).
</p>
<fig id="F4" orientation="portrait" position="float">
<label>Fig. 4</label>
<caption>
<p>
Genotype- and phenotype-
guided risk classification
of long QT syndrome
patients. Phenotype-guided
recommendations are
indicated by orange text,
Genotype-guided recommendations
are indicated by
purple text, and a combination
of genotype- and phenotype-
guided recommendations
is indicated by black
text within the figure. LQTS,
long QT syndrome; Arrythm.
events, arrhythmic events;
AP-LQTS1, autosomal recessive
LQTS; JLNS, Jervell-
Lange-Nielsen syndrome; TS,
Timothy syndrome.
</p>
</caption>
<graphic xlink:href="AN20758251-29-062-g004"></graphic>
</fig>
<p>
Currently, beta-blockers are the only class of drugs recommended for patients
with LQTS - [<xref ref-type="bibr" rid="R22">22</xref>, <xref ref-type="bibr" rid="R23">23</xref>]. They are particularly effective in LQTS1 patients whose
trigger factors are physical exercise and whose tone of the sympathetic nervous
system is significantly elevated. The protective effect of beta-blockers is
less pronounced in LQTS2 and LQTS3.
</p>
<p>
In addition to drug therapy, the frequency of arrhythmic events in LQTS
patients can be reduced by extrapleural or thoracoscopic left-sided cardiac
sympathectomy, including removal of the lower half of the stellate ganglion
(T1) and thoracic ganglia (T2–T4). Schwartz <italic>et al</italic>. have
demonstrated a decrease in the frequency of arrhythmic events by more than 90%
within 8 years after surgical denervation in a group of 147 high-risk LQTS
patients (average QTc 563 Ѓ} 65 ms; 99% symptomatic) [<xref ref-type="bibr" rid="R24">24</xref>].Modern concepts suggest the use of
left-sided cardiac sympathectomy in patients who cannot tolerate
β-blockers or for whom they are inefficient [<xref ref-type="bibr" rid="R22">22</xref>].
</p>
<p>
The decision about implantation of a cardioverter- defibrillator (ICD) should
be made on an individual basis. According to the observation of 233 LQTS
patients within &lt; 5 years after ICD implantation, 28% of them underwent
efficient electrotherapy. At the same time, at least 31% of them had at least
one post-implantation complication [<xref ref-type="bibr" rid="R25">25</xref>].
In 2012, Schwartz <italic>et al</italic>. developed a clinical M-FACT scale to
identify patients in need of ICD
(<italic><xref ref-type="table" rid="T2">Table 2</xref></italic>). According
to the authors, implantation of ICD is justified at a score of ≥ 1 point.
</p>
<table-wrap id="T2" orientation="portrait" position="float">
<label>Table 2</label>
<caption>
<p>
M-FACT risk scale for a decision on implantation
of cardioverter-defibrillator in patients with long QT syndrome
(Schwartz et al., 2012) [<xref ref-type="bibr" rid="R26">26</xref>]
</p>
</caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th colspan="1" rowspan="1">Criteria</th>
<th colspan="1" rowspan="1">
– 1<break></break>
point
</th>
<th colspan="1" rowspan="1">
0<break></break>
points
</th>
<th colspan="1" rowspan="1">
1<break></break>
point
</th>
<th colspan="1" rowspan="1">
2<break></break>
points
</th>
</tr>
</thead>
<tbody>
<tr>
<td align="center" colspan="1" rowspan="1">
Event free on therapy for
&gt;10 y
</td>
<td align="center" colspan="1" rowspan="1">Yes</td>
<td align="center" colspan="1" rowspan="1"> </td>
<td align="center" colspan="1" rowspan="1"> </td>
<td align="center" colspan="1" rowspan="1"> </td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1">QTc, ms</td>
<td align="center" colspan="1" rowspan="1"> </td>
<td align="center" colspan="1" rowspan="1">≤ 500</td>
<td align="center" colspan="1" rowspan="1">
&gt; 500
≤ 550
</td>
<td align="center" colspan="1" rowspan="1"> &gt; 550</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1">Prior ACA</td>
<td align="center" colspan="1" rowspan="1"> </td>
<td align="center" colspan="1" rowspan="1">No</td>
<td align="center" colspan="1" rowspan="1">Yes</td>
<td align="center" colspan="1" rowspan="1"> </td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1">Events on therapy</td>
<td align="center" colspan="1" rowspan="1"> </td>
<td align="center" colspan="1" rowspan="1">No</td>
<td align="center" colspan="1" rowspan="1">Yes</td>
<td align="center" colspan="1" rowspan="1"> </td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1">Age at implant, years</td>
<td align="center" colspan="1" rowspan="1"> </td>
<td align="center" colspan="1" rowspan="1"> &gt; 20</td>
<td align="center" colspan="1" rowspan="1"> ≤ 20</td>
<td align="center" colspan="1" rowspan="1"> </td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="TF2-1">
<p>
Note. M-FACT is deciphered as M for Minus 1 point for
being free of cardiac events, while on therapy for &gt;10 y;
F for Five hundred and Five hundred and Fifty millisecond
QTc; A for Age ≤20 y at implant; C for Cardiac arrest; T
for events on Therapy; ACA, aborted cardiac arrest.
</p>
</fn>
</table-wrap-foot>
</table-wrap>
<p>
<bold>Short QT interval syndrome (SQTS)</bold>
</p>
<p>
The short QT interval syndrome (SQTS) was first described as late as in 2000.
This repolarization disorder is characterized by QT shortened to 320 ms and
lower, high T-wave, and relative increase in the interval between the peak and
the end of the T-wave [<xref ref-type="bibr" rid="R27">27</xref>]. However,
according to population studies, shortening of the QT interval does not always
imply true congenital SQTS and is not always accompanied by susceptibility to
life-threatening arrhythmias [<xref ref-type="bibr" rid="R28">28</xref>]. In
addition to a consistently shortened QT, patients with congenital SQTS are
characterized by shortening of the ST segment up to its complete absence and
start of the T-wave directly from the S-wave.
</p>
<p>
The shortening of the QT interval, as well as its prolongation, is associated
with life-threatening arrhythmias and SCD, often in childhood. Mutations in six
different genes encoding subunits of the K<sup>+</sup>
(<italic>KCNQ1</italic>,<italic> KCNH2</italic>, <italic>KCNJ2</italic>) or
Ca<sup>2+</sup> (<italic>CACNA1C</italic>, <italic>CACNB2</italic>,
<italic>CACNA2D1</italic>) channel have been identified as associated with this
phenotype. Many of these genes are similar to those implicated in LQTS:
however, the functional outcome of the mutations is exactly the opposite.
Gainof- function mutations of K<sup>+</sup>-channels genes lead to increased
repolarization and shortening of the action potential. Mutations in
Ca<sup>2+</sup>-channels genes, on the contrary, lead to loss-of-function.
</p>
<p>
A diagnosis of SQTS can be established at QTc ≤ 340 ms. At QTc ≤
360 ms, the diagnosis is valid in the presence of characteristic genetic
mutations, family history of SQTS, familial cases of sudden death at an age
&lt; 40 years or VT/VF episodes without cardiac pathology [<xref ref-type="bibr" rid="R21">21</xref>].
</p>
<p>
According to the latest European guidelines, implantation of a
cardioverter-defibrillator is advised only as a secondary prevention. Sotalol
or quinidine can be used as antiarrhythmic therapy (recommendation grade IIb)
[<xref ref-type="bibr" rid="R21">21</xref>].
</p>
<p>
<bold>Brugada syndrome (BS)</bold>
</p>
<p>
Patients with the Brugada syndrome are prone to developing fatal arrhythmias
mainly during sleep, in the absence of myocardial ischemia, electrolyte
abnormalities, and structural heart diseases [<xref ref-type="bibr" rid="R13">13</xref>].
Changes in resting ECG characteristics for BS patients
are wellknown: ST-segment elevation in the right precordial leads, signs of a
right bundle branch blockage combined with normal duration of the QT interval
(<italic><xref ref-type="fig" rid="F5">Fig. 5</xref></italic>).
Prescription of Na<sup>+</sup>-channels blockers
(procainamide, flecainide, ajmaline), as well as fever, may reveal hidden ECG
disorders. Cases of unexplained sudden death in the family history are quite
typical. The prevalence of the Brugada syndrome in Europe and America is about
1:10,000 of population [<xref ref-type="bibr" rid="R13">13</xref>].
</p>
<fig id="F5" orientation="portrait" position="float">
<label>Fig. 5</label>
<caption>
<p>
ECG of a patient with Brugada syndrome (own data)
</p>
</caption>
<graphic xlink:href="AN20758251-29-062-g005"></graphic>
</fig>
<p>
A total of 350 different variants of gene mutations associated with BS
[<xref ref-type="bibr" rid="R29">29</xref>] [<xref ref-type="bibr" rid="R30">30</xref>]
has been described to date: in 30% of cases, they are
mutations in the <italic>SCN5A </italic>gene that encodes the α-subunit of
rapid Na+-channels; in 5%, mutations in other genes, including those encoding
Ca<sup>2+</sup>- and K<sup>+</sup> channels proteins; and in 65% of cases, the
genetic substrate is not identified [<xref ref-type="bibr" rid="R31">31</xref>,
<xref ref-type="bibr" rid="R32">32</xref>]. <italic>SCN5A</italic> gene
mutations lead to a decrease in the number of Na+-channels and acceleration of
their inactivation in the right ventricular epicardium cells, which locally
reduces<italic> I</italic><sub>Na</sub> in the epicardium. The resulting
disruption of ventricle wall repolarization leads to a transmural voltage
gradient, which manifests itself at ECG as ST-segment elevation and serves as a
substrate for re-entry into the ventricular myocardium
[<xref ref-type="bibr" rid="R33">33</xref>].
</p>
<p>
According to other researchers, the inhibition of the inward sodium current
slows down pulse conduction in the right ventricle, causing delayed activation
of the myocardium in the right ventricular exit sites. This leads to
asynchronous depolarization and electrical instability in this section of the
heart with possible development of ventricular arrhythmias by the re-entry
mechanism [<xref ref-type="bibr" rid="R13">13</xref>, <xref ref-type="bibr" rid="R34">34</xref>]. It is unclear whether these two hypotheses are mutually
exclusive or if all BS variants are subject to a single pathophysiological
mechanism.
</p>
<p>
A genetic analysis to identify mutations in genes typical for BS is useful for
verification of the diagnosis, but it has no independent value in the risk
stratification. Moreover, the absence of mutations does not preclude the
diagnosis
</p>
<p>
Risk stratification in asymptomatic patients with Brugada syndrome is the most
important and, at the same time, controversial issue. The annual incidence of
cardiac arrest or syncopes in BS patients with a history of sustained VT or VF
is between 1.9 [<xref ref-type="bibr" rid="R35">35</xref>] and 8.8
[<xref ref-type="bibr" rid="R36">36</xref>], 7.7 [<xref ref-type="bibr" rid="R37">37</xref>] and 13.8% [<xref ref-type="bibr" rid="R38">38</xref>],
respectively. Implantation of ICD to such patients is the only truly effective
treatment [<xref ref-type="bibr" rid="R37">37</xref>]. However, most patients
(64% according to a large-scale FINGER study) [<xref ref-type="bibr" rid="R35">35</xref>] have no clinical manifestations of the disease at the time
of verification of the diagnosis. The incidence of arrhythmic events in such
patients is significantly lower and ranges from 0 to 0.8% (0.5% according to
FINGER data) [<xref ref-type="bibr" rid="R37">37</xref>]. On the other hand,
the young age of these patients and the absence of structural heart diseases
suggest that a low annual risk of cardiac events is only temporary and will
increase in the subsequent few decades.
</p>
<p>
The role of programmed ventricular stimulation in invasive EPS for risk
stratification in asymptomatic patients has been actively discussed since BS
was described for the first time. Recent studies, including the largest ones,
FINGER and PRELUDE, found no independent effect of invasive electrophysiologic
studies on arrhythmic events over an average of 32 and 18 months
[<xref ref-type="bibr" rid="R35">35</xref>, <xref ref-type="bibr" rid="R38">38</xref>].
However, according to a recently published meta-analysis
of 14 studies, which included 3,536 patients with an asymptomatic Brugada
syndrome phenotype, a typical spontaneous pattern of type 1 ECG (i.e. ST
elevation in the right precordial leads of more than 2 mm with a negative
T-wave and J-wave)
(<italic><xref ref-type="fig" rid="F5">Fig. 5</xref></italic>),
as well as the induction of
ventricular tachyarrhythmias by the programmed ventricular stimulation,
increases the risk of future arrhythmic events. The length of the follow-up
period was 20 to 77 months [<xref ref-type="bibr" rid="R39">39</xref>].
Therefore, at the moment the recommendation of ICD implantation on the basis of
EPS data has class of recommendation IIb; i.e., “can be considered”
for the induction of VF during the programmed ventricular stimulation with two
or three extrastimules in two points (Clinical Recommendations for Diagnosis
and Treatment of Ventricular Arrhythmias, European Society of Cardiology, 2015)
[<xref ref-type="bibr" rid="R21">21</xref>].
</p>
<p>
In other cases, ICD implantation is indicated for BS patients as secondary
prevention (class of recommendation I), and it should be considered in case of
a spontaneous manifestation of type I ECG and history of syncope of unknown
origin (class of recommendation IIa) [<xref ref-type="bibr" rid="R21">21</xref>]. Quinidine and isoproterenol are recommended as preventive
antiarrhythmic therapy, including for the treatment of “electrical
storm” (class of recommendation IIa). In addition, BS patients are
advised to observe a number of rules to minimize the known factors that trigger
arrhythmia, such as excluding administration of drugs that can aggravate ST
elevation in the right precordial leads, avoiding excessive use of alcohol and
heavy meals, and using antipyretics in a fever of any origin as soon as
possible [<xref ref-type="bibr" rid="R21">21</xref>].
</p>
<p>
<bold>Catecholaminergic polymorphic ventricular tachycardia (CPVT)</bold>
</p>
<p>
Disruption of intracellular Ca<sup>2+</sup> homeostasis leads to serious
arrhythmogenic effects. Mutations in the <italic>RyR2</italic> gene encoding
the ryanodine receptors that are responsible for the release of calcium from
the sarcoplasmic reticulum of the cardiomyocyte cause the development of an
autosomal dominant variant of catecholaminergic polymorphic ventricular
tachycardia. Autosomal recessive types of the disorder are caused by
impairments of the <italic>CASQ2 </italic>gene function, which encodes the
calsequestrin protein that binds Ca<sup>2+</sup> of the sarcoplasmic reticulum,
or mutations in the <italic>TRDN </italic>gene that encodes triadin which binds
calsequestrin to RyR2-receptors [<xref ref-type="bibr" rid="R13">13</xref>].
These three proteins are located in the terminal SPR cistern, where the
intracellular membrane is in close proximity to the region of transverse
tubulae (T-tubulae) of the plasma membrane. Normally, electrical pulses are
delivered into the T-tubulae system and activate L-type
Ca<sup>2+</sup>-channels, causing fluctuations in Ca<sup>2+</sup> concentration
sufficient to cause a Ca<sup>2+</sup>-induced release of Ca<sup>2+</sup> via
ryanodine receptors. Release of Ca<sup>2+</sup> from the SPR causes contraction
of the myocyte, which ends in the removal of Ca<sup>2+</sup> from the cytosol,
mainly via the Ca<sup>2+</sup>-ATP-ase and Na<sup>+</sup>/Ca<sup>2+</sup>
pumps. Disruption of the function of these receptors leads to cardiomyocyte
overload with Ca<sup>2+</sup>, electrical instability of the cells, and the
formation of post-depolarization potentials. Catecholamines that enter the
blood in time of stress and/ or exercise cause contraction of the heart muscle
via phosphorylation of protein kinase of the ryanodine receptor [<xref ref-type="bibr" rid="R40">40</xref>-<xref ref-type="bibr" rid="R42">42</xref>].
</p>
<p>
Other genes associated with polymorphic VT have also been identified. It is
believed that mutation in the<italic> KNJ2 </italic>gene, which is associated
with the development of the Andersen syndrome, may be the cause of familial
catecholaminergic VT. There are reports on mutations in the ankyrin B gene,
which are also present in LQTS4. Recently, it has been suggested that
idiopathic ventricular fibrillation can be a form of familial polymorphic
ventricular tachycardia [<xref ref-type="bibr" rid="R43">43</xref>].
</p>
<p>
The diagnosis of catecholaminergic polymorphic VT is basically an exclusion
diagnosis in which bi-directional VT or VF in response to physical or emotional
stress occurs in patients without a structural heart disease and changes in
resting ECG.
</p>
<p>
Drug therapy consists of the prescription of beta- blockers. There are several
reports on the effectiveness of calcium channel blockers (verapamil) in
familial polymorphic ventricular tachycardia. In general, a lifestyle change is
indicated to all patients, including exclusion of physical activities and
exercise.
</p>
<p>
<bold>Idiopathic ventricular fibrillation</bold>
</p>
<p>
Idiopathic ventricular fibrillation is a rare disease of unknown etiology,
which manifests itself as syncope and SCD in the absence of data in favor of an
organic heart disease or canalopathy. Idiopathic VF is characterized by
spontaneous development of fatal arrhythmia unrelated to physical stress, often
during sleep. VF is initiated by premature ventricular contraction with a very
short coupling interval. It has been demonstrated that Purkinje fibers are
involved in the induction and maintenance of arrhythmia with a re-entry
mechanism [<xref ref-type="bibr" rid="R44">44</xref>].
</p>
<p>
<bold>Arrhythmogenic right ventricular dysplasia (ARVD)</bold>
</p>
<p>
Arrhythmogenic right ventricular dysplasia (or cardiomyopathy) (ARVD) is a rare
inherited disease characterized by ventricular arrhythmias, sudden cardiac
death, and dysfunction of the right ventricle. More than 30 years have passed
since the first detailed description of ARVD in 1982. Numerous clinical and
experimental studies of this disease have been published since. For example, it
has been established that the most common genetic causes of ARVD are mutations
in desmosome proteins, the basic elements of cell-cell adhesion structures
present in the multilayered epithelium and the myocardium; e.g., the results of
a recently published study involving 577 patients in the U.S. (Johns Hopkins
registry) and Danish ARVD registers showed that 80% of patients had a mutation
in the <italic>PKP2 </italic>gene encoding plakophilin, one of the desmosomal
proteins. The remaining participants in the study had mutations in other
desmosomal protein genes: <italic>DSG2 </italic>(desmoglein),
<italic>PLN</italic> (plakophilin), <italic>DSP </italic>(desmoplakin),
<italic>DSC2 </italic>(desmocollin),<italic> JUP </italic>(junction
plakoglobin), <italic>TMEM43 </italic>(transmembrane protein 43) [<xref ref-type="bibr" rid="R45">45</xref>].
</p>
<p>
This myocardium dysplasia can be called “cardiomyopathy of intercellular
contacts” [<xref ref-type="bibr" rid="R11">11</xref>]. Defective
desmosomal proteins disrupt the mechanical connection between adjacent muscle
cells, which leads to their separation, especially in the context of myocardial
stretching. The accompanying inflammation, fibrosis, and adipocytosis may be a
nonspecific response to damage, similar to the one caused by any damage to the
myocardium [<xref ref-type="bibr" rid="R46">46</xref>]. This pathogenetic model
explains the fact that prolonged excessive stress, accompanied by myocardial
stretching, significantly increases the risk of early clinical manifestation of
the disease and increases the risk of SCD. In addition, it explains why the
pathological ARVD process often involves the more stretchable and thin-walled
right ventricle, especially in the early stages of the disease. Naturally, the
mechanical separation leads to electrical heterogeneity, forming an ideal
substrate for the development of ventricular re-entry tachycardia [<xref ref-type="bibr" rid="R11">11</xref>].
</p>
<fig id="F6" orientation="portrait" position="float">
<label>Fig. 6</label>
<caption>
<p>
Cardiac MRI of a patient with ARVD (own data).
Bright blood images in the right ventricular outflow tract
(RVOT) plane obtained in end diastole (A) and end systole
(B) show microaneurysms (arrows) in the right ventricle
free wall with persistent bulge in both phases. Short-axis
bright blood images obtained in end diastole (C) and
end systole (D) demonstrate dyskinesis (bulge in systole,
arrows) at the acute angle of the right ventricle
</p>
</caption>
<graphic xlink:href="AN20758251-29-062-g006"></graphic>
</fig>
<p>
Task Force Criteria (TFC) for the diagnosis of ARVD were proposed in 1994 and
revised in 2010 [<xref ref-type="bibr" rid="R47">47</xref>].
The diagnostic criteria for ARVD include characteristic
changes in depolarization/repolarization on the electrocardiogram,
echocardiography, and magnetic resonance imaging (MRI) data
(<italic><xref ref-type="fig" rid="F6">Fig. 6</xref></italic>)
describing changes in morphology and function of the right
ventricle, characteristic changes in myocardial tissue observed in
endomyocardial biopsy, as well as the presence of ventricular arrhythmias,
details of family history and genetic testing
(<italic><xref ref-type="table" rid="T3">Table 3</xref></italic>). To
justify an ARVD diagnosis, a patient must score four points, with one major
criterion being worth two points, and one minor criterion being worth one
point. ARVD is considered to be “probable” at three points, whereas
a score between one and two should be considered as an absence of ARVD [47].
</p>
<table-wrap id="T3" orientation="portrait" position="float">
<label>Table 3</label>
<caption>
<p>
Diagnostic criteria for arrhythmogenic right ventricular dysplasia (ARVD) (F. Marcus et al., 2010)
[<xref ref-type="bibr" rid="R47">47</xref>]
</p>
</caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th colspan="1" rowspan="1">Group</th>
<th colspan="1" rowspan="1">Major criterion</th>
<th colspan="1" rowspan="1">Minor criterion</th>
</tr>
</thead>
<tbody>
<tr>
<td align="center" colspan="1" rowspan="1">
Global or<break></break>
regional<break></break>
dysfunction<break></break>
and structural<break></break>
alterations
</td>
<td align="center" colspan="1" rowspan="1">
<bold>By 2D echo:</bold><break></break>
Regional RV akinesia, dyskinesia, or aneurysm
AND 1 of the following (end diastole):
PLAX RVOT 32 mm
PSAX RVOT 36 mm OR
fractional area change 33%;<break></break>
<bold>By MRI:</bold><break></break>
Regional RV akinesia or dyskinesia or dyssynchronous
RV contraction
AND 1 of the following:
Ratio of RV end-diastolic volume to BSA 110
mL/m2 (male) or 100 mL/m2 (female)
RVEF ≤ 40%<break></break>
<bold>By RV angiography:</bold><break></break>
Regional RV akinesia, dyskinesia, or aneurysm
</td>
<td align="center" colspan="1" rowspan="1">
<bold>By 2D echo:</bold><break></break>
Regional RV akinesia or dyskinesia or dyssynchronous
RV contraction
AND 1 of the following (end diastole):
PLAX RVOT 29 to 32 mm;
PSAX RVOT 32 to 36 mm OR
fractional area change 33% to 40%;<break></break>
<bold>By MRI:</bold><break></break>
Regional RV akinesia or dyskinesia or dyssynchronous
RV contraction
AND 1 of the following:
Ratio of RV end-diastolic volume to BSA 100 to 110
mL/m2 (male) or 90 to 100 mL/m2 (female);
RVEF&gt; 40 ≤45%
</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1">Tissue<break></break>characterization<break></break>of wall</td>
<td align="center" colspan="1" rowspan="1">
Residual myocytes 60% by morphometric
analysis (or 50% if estimated), with fibrous
replacement of the RV free wall myocardium in
1 sample, with or without fatty replacement of
tissue on endomyocardial biopsy
</td>
<td align="center" colspan="1" rowspan="1">
Residual myocytes 60% to 75% by morphometric
analysis (or 50% to 65% if estimated), with fibrous
replacement of the RV free wall myocardium in 1
sample, with or without fatty replacement of tissue on
endomyocardial biopsy
</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1">
Repolarization
abnormalities
</td>
<td align="center" colspan="1" rowspan="1">
Inverted T waves in right precordial leads (V<sub>1</sub>,
V<sub>2</sub>, and V<sub>3</sub>) or beyond in individuals 14 years
of age (in the absence of complete right bundle-branch block)
</td>
<td align="center" colspan="1" rowspan="1">
Inverted T waves in leads V<sub>1</sub> and V<sub>2</sub> in individuals 14
years of age (in the absence of complete right bundle-branch block) or in V<sub>4</sub>, V<sub>5</sub>, or V<sub>6</sub>
Inverted T waves in leads V<sub>1</sub>, V<sub>2</sub>, V<sub>3</sub>, and V<sub>4</sub> in individuals
14 years of age in the presence of complete right bundle-branch block</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1">
Depolarization/
conduction
abnormalities
</td>
<td align="center" colspan="1" rowspan="1">
Epsilon wave (reproducible low-amplitude
signals between end of QRS complex to onset
of the T wave) in the right precordial leads (V<sub>1</sub> to V<sub>3</sub>)
</td>
<td align="center" colspan="1" rowspan="1">
Late potentials by SAECG in 1 of 3 parameters in the absence of a QRS duration of 110 ms
on the standard ECG:<break></break>fQRS ≥ 114 ms<break></break>
Duration of terminal QRS 40 µV (low-amplitude signal duration) 38 ms<break></break>
Root-mean-square voltage of terminal 40 ms QRS ≤ 20 ms<break></break>
Terminal activation duration of QRS 55 ms measured
from the nadir of the S wave to the end of the QRS,
including R’, in V<sub>1</sub>, V<sub>2</sub>, or V<sub>3</sub>, in the absence of complete
right bundle-branch block
</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1">Arrhythmias</td>
<td align="center" colspan="1" rowspan="1">
Nonsustained or sustained ventricular tachycardia
of left bundle-branch morphology with
superior axis (negative or indeterminate QRS in
leads II, III, and aVF and positive in lead aVL)
</td>
<td align="center" colspan="1" rowspan="1">
Nonsustained or sustained ventricular tachycardia of
RV outflow configuration, left bundle-branch block
morphology with inferior axis (positive QRS in leads II,
III, and aVF and negative in lead aVL) or of unknown
axis<break></break>500 ventricular extrasystoles per 24 hours (Holter)
</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1">Family history</td>
<td align="center" colspan="1" rowspan="1">
ARVC/D confirmed in a first-degree relative
who meets current Task Force criteria
ARVC/D confirmed pathologically at autopsy
or surgery in a first-degree relative
Identification of a pathogenic mutation†
categorized as associated or probably associated
with ARVC/D in the patient under evaluation
</td>
<td align="center" colspan="1" rowspan="1">
History of ARVC/D in a first-degree relative in whom
it is not possible or practical to determine whether the
family member meets current Task Force criteria
Premature sudden death (35 years of age) due to
suspected ARVC/D in a first-degree relative
ARVC/D confirmed pathologically or by current Task
Force Criteria in second-degree relative
</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="TF3-1">
<p>
BSA, body surface area; RVOT, RV outflow tract; PVC, premature ventricular contraction; EDV RV, end-diastolic volume
of the right ventricle; LBBB - left bundle branch block; RV – right ventricle; PLAX parasternal long-axis view; PSAX,
parasternal short-axis view; RVEF, right ventricle ejection fraction; CM – Holter ECG monitoring; Echo, echocardiography;
EMB – endomyocardial biopsy.
</p>
</fn>
</table-wrap-foot>
</table-wrap>
<p>
Proper treatment of ARVD patients largely depends on an adequate diagnosis.
Treatment is defined by the following strategies: SCD risk stratification and
addressing the issue of implanting a cardioverter-defibrillator (ICD),
minimizing the frequency of ICD discharges, and prevention of the progression
of the disease. According to the general recommendations for SCD prevention,
ICD implantation in ARVD is indicated in patients who have had ventricular
fibrillation, or sustained ventricular tachycardia or syncope. The study by
Bhonsale A. <italic>et al</italic>. included 84 patients with ARVD who were
followed for 4.7 ± 3.4 years after ICD implantation as primary prevention.
The predictors of effective electrotherapy were the symptoms (i.e. the status
of the subject and not that of a family member), induction of VT at
electrophysiological study, presence of unstable ventricular tachycardia, and
more than 1,000 premature ventricular contractions (PVC) per day. The induction
of ventricular tachyarrhythmias at EPS was an independent risk factor for the
effective discharge of ICD [<xref ref-type="bibr" rid="R48">48</xref>].
</p>
<p>
Therefore, currently ICD implantation is indicated for patients who meet TFC
criteria, especially if they have a history of SCD, sustained VT or
arrhythmogenic syncope, a high number of PVCs, and/or unstable VT
[<xref ref-type="bibr" rid="R46">46</xref>]. Clinicians should be especially attentive
to SCD risk stratification in patients for whom ARVD was identified during a
family screening. Typically, such patients are at earlier stages of the
disease. Limitation on physical activity and the use of β-blockers can
reduce the risk of SCD in such individuals. However, careful monitoring of the
patient’s condition is recommended for all patients with a decision not
to implant ICD.
</p>
<p>
β-blockers are indicated for all patients with ARVD. Amiodarone, or
sotalol is recommended as additional antiarrhythmic therapy. In rare cases,
other antiarrhythmic agents are used. If antiarrhythmics and repetitive ICD
discharges are ineffective, it is recommended to perform radiofrequency
ablation of arrhythmogenic foci. It should be noted that the role of catheter
ablation in patients with ARVD is limited to a possible reduction in the number
of defibrillator discharges and improved quality of life. According to several
studies on the effectiveness of catheter ablation in patients with ARVD, only
25 to 47% were VT-free during the first year of observation, and 5 and 10 years
after surgery the numbers were 21 and 15% [<xref ref-type="bibr" rid="R46">46</xref>].
Efficacy of epicardial ablation is slightly higher and
amounts to 64% during the first year and 45% after 5 years
[<xref ref-type="bibr" rid="R46">46</xref>].
According to Philips B. <italic>et
al</italic>., in 30 patients with ARVD there were no effective ICD discharges
after epicardial radiofrequency ablation in 83, 76, and 70% of cases for 6, 12,
and 24 months, respectively [<xref ref-type="bibr" rid="R49">49</xref>].
</p>
<p>
The only currently available effective way to slow the progression of the
disease is limitation on physical activity.
</p>
</sec>
<sec>
<title>CONCLUSION</title>
<p>
In conclusion, we would like to present the survey data published in 2014 by
the European Heart Rhythm Association, which included cardiologists from 50
clinics in 23 countries [<xref ref-type="bibr" rid="R50">50</xref>]. The survey
focused on the diagnosis and treatment of patients with congenital arrhythmic
syndromes. According to the study, most patients with canalopathies undergo
genetic testing: from 70% among LQTS to 36% among patients with idiopathic VF.
Although only a third of clinicians discuss the test results with patients and
specialists in genetics, pharmacological tests are relatively frequently used
for the diagnosis of congenital canalopathies. For example, 89% of the
respondents used sodium channel blockers for the diagnosis of the Brugada
syndrome, and 36% used isoproterenol to confirm catecholaminergic ventricular
tachycardia. 80–92% of the doctors do not use pharmacological provocation
for the diagnosis of the remaining canalopathies. Most clinics (82–98%)
do not resort to intracardiac EPS to induce ventricular arrhythmias, with the
exception of BS cases (39% of clinics use EFI). From 27 to 54% of the study
participants included MRI in the diagnostic protocol for patients with BS and
idiopathic ventricular arrhythmias, but only rarely for patients with LQTS and
SQTS (11–17% of participants). Coronary angiography is performed in 62%
of cases of idiopathic VF/VT. Endomyocardial biopsy is included in the study
protocol of 8% of the patients with idiopathic VF. In most clinical centers,
ICD implantation for primary prevention is performed only in 0–5% of
patients with congenital canalopathies, whereas ICD usage for secondary
prevention increases to 90–100%. Recurrent ventricular arrhythmias,
leading to multiple ICD discharges, are treated with intensification of
therapy, the use of β-blockers, and various antiarrhythmic drugs
(isoproterenol infusion, quinidine at SQTS), and cardiac sympathetic
denervation. Radiofrequency ablation (RFA) is considered to be the preferred
method in idiopathic ventricular fibrillation (20%), whereas for the remaining
canalopathies the frequency of RFA use does not exceed 8%.
</p>
<p>
The authors of the survey conclude that the study participants share a
commitment to the present recommendations; however, they point out that more
than 50% of all centers participating in the survey do not participate in any
of the registers (local, national or international), which, of course,
complicates the task of studying the course of the disease, effectiveness of
therapy, risk stratification, and prognosis in patients with primary
arrhythmogenic syndromes.
</p>
</sec>
</body>
<back>
<ack>
<p>
This work was supported by a grant from the Government of the Russian
Federation for state support of scientific research conducted under the
supervision of leading scientists at Russian scientific institutions and public
research centers of the Russian Federation “Molecular mechanisms of
atrial fibrillation” (№ 14.Z50.31.0026).
</p>
</ack>
<glossary>
<def-list>
<title>Abbreviations</title>
<def-item>
<term id="G01">ARVD</term>
<def>
<p>arrhythmogenic right ventricular dysplasia</p>
</def>
</def-item>
<def-item>
<term id="G02">SCD</term>
<def>
<p>sudden cardiac death</p>
</def>
</def-item>
<def-item>
<term id="G03">CAD</term>
<def>
<p>coronary artery disease</p>
</def>
</def-item>
<def-item>
<term id="G04">ICD</term>
<def>
<p>implantable cardioverter-defibrillator</p>
</def>
</def-item>
<def-item>
<term id="G05">CPVT</term>
<def>
<p>catecholaminergic polymorphic ventricular tachycardia</p>
</def>
</def-item>
<def-item>
<term id="G06">LV</term>
<def>
<p>left ventricle</p>
</def>
</def-item>
<def-item>
<term id="G07">MRI</term>
<def>
<p>magnetic-resonance imaging</p>
</def>
</def-item>
<def-item>
<term id="G08">VT</term>
<def>
<p>ventricular tachycardia</p>
</def>
</def-item>
<def-item>
<term id="G09">BS</term>
<def>
<p>Brugada syndrome</p>
</def>
</def-item>
<def-item>
<term id="G10">SPR</term>
<def>
<p>sarcoplasmic reticulum</p>
</def>
</def-item>
<def-item>
<term id="G11">LV EF</term>
<def>
<p>left ventricular ejection fraction</p>
</def>
</def-item>
<def-item>
<term id="G12">VF</term>
<def>
<p>ventricular fibrillation</p>
</def>
</def-item>
<def-item>
<term id="G13">CHF</term>
<def>
<p>congestive heart failure</p>
</def>
</def-item>
<def-item>
<term id="G14">ECG</term>
<def>
<p>electrocardiography</p>
</def>
</def-item>
<def-item>
<term id="G15">PEA</term>
<def>
<p>pulseless electrical activity</p>
</def>
</def-item>
<def-item>
<term id="G16">EPS</term>
<def>
<p>electrophysiological study</p>
</def>
</def-item>
<def-item>
<term id="G17">cAMF</term>
<def>
<p>cyclic adenosin monophosphate</p>
</def>
</def-item>
<def-item>
<term id="G18">HCN-cannels</term>
<def>
<p>hyperpolarized activated channels</p>
</def>
</def-item>
<def-item>
<term id="G19">LQTS</term>
<def>
<p>long QT syndrome</p>
</def>
</def-item>
<def-item>
<term id="G20">SQTS</term>
<def>
<p>short QT syndrome</p>
</def>
</def-item>
</def-list>
</glossary>
<ref-list>
<title>References</title>
<ref id="R1">
<label>1</label>
<element-citation publication-type="journal">
<source/>Heart Rhythm
          <year>2006</year>
<volume>3</volume>
<fpage>108</fpage>
<lpage>113</lpage>
<name>
<surname>Zipes</surname>
<given-names>D.P.</given-names>
</name>
<name>
<surname>Rubart</surname>
<given-names>M.</given-names>
</name>
<pub-id pub-id-type="pmid">16399065</pub-id>
</element-citation>
</ref>
<ref id="R2">
<label>2</label>
<element-citation publication-type="journal">
<source/>Circulation.
          <year>2010</year>
<volume>122</volume>
<fpage>2335</fpage>
<lpage>2348</lpage>
<name>
<surname>Fishman</surname>
<given-names>G.I.</given-names>
</name>
<name>
<surname>Chugh</surname>
<given-names>S.S.</given-names>
</name>
<name>
<surname>Dimarco</surname>
<given-names>J.P.</given-names>
</name>
<name>
<surname>Albert</surname>
<given-names>C.M.</given-names>
</name>
<name>
<surname>Anderson</surname>
<given-names>M.E.</given-names>
</name>
<name>
<surname>Bonow</surname>
<given-names>R.O.</given-names>
</name>
<name>
<surname>Buxton</surname>
<given-names>A.E.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>P.S.</given-names>
</name>
<name>
<surname>Estes</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Jouven</surname>
<given-names>X.</given-names>
</name>
<pub-id pub-id-type="pmid">21147730</pub-id>
</element-citation>
</ref>
<ref id="R3">
<label>3</label>
<element-citation publication-type="book">
<source/>Clinical guidelines for electrophysiological studies, catheter ablation and implantable antiarrythmic devices usage. M.: MAKS Press; 2013 (in Russian)
          <year>2013</year>
<fpage>596</fpage>
<name>
<surname>Revishvili</surname>
<given-names>A.Sh.</given-names>
</name>
<name>
<surname>Ardashev</surname>
<given-names>A.V.</given-names>
</name>
<name>
<surname>Bojcov</surname>
<given-names>S.A.</given-names>
</name>
<name>
<surname>Bockeria</surname>
<given-names>L.A.</given-names>
</name>
<name>
<surname>Golukhova</surname>
<given-names>E.Z.</given-names>
</name>
<name>
<surname>Davtyan</surname>
<given-names>K.V.</given-names>
</name>
<name>
<surname>Zenin</surname>
<given-names>S.A.</given-names>
</name>
<name>
<surname>Kuznetcov</surname>
<given-names>V.A.</given-names>
</name>
<name>
<surname>Kupcov</surname>
<given-names>V.V.</given-names>
</name>
<name>
<surname>Lebedev</surname>
<given-names>D.S.</given-names>
</name>
</element-citation>
</ref>
<ref id="R4">
<label>4</label>
<element-citation publication-type="book">
<source/>Sudden cardiac death. M.: GEOTAR-Media; 2011. (in Russian)
          <year>2011</year>
<fpage>272</fpage>
<name>
<surname>Bockeria</surname>
<given-names>L.A.</given-names>
</name>
<name>
<surname>Revishvili</surname>
<given-names>A.Sh.</given-names>
</name>
<name>
<surname>Neminshchii</surname>
<given-names>I.M.</given-names>
</name>
</element-citation>
</ref>
<ref id="R5">
<label>5</label>
<element-citation publication-type="journal">
<source/>Prog. Cardiovasc Dis.
          <year>2008</year>
<volume>51(3)</volume>
<elocation-id></elocation-id>
<fpage>213</fpage>
<lpage>228</lpage>
<name>
<surname>Chugh</surname>
<given-names>S.S.</given-names>
</name>
<name>
<surname>Reinier</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Teodorescu</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Evanado</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Kehr</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Al Samara</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Mariani</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Gunson</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Jui</surname>
<given-names>J.</given-names>
</name>
<pub-id pub-id-type="pmid">19026856</pub-id>
</element-citation>
</ref>
<ref id="R6">
<label>6</label>
<element-citation publication-type="journal">
<source/>JAMA.
          <year>2008</year>
<volume>300</volume>
<fpage>1423</fpage>
<lpage>1431</lpage>
<name>
<surname>Nichol</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Thomas</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Callaway</surname>
<given-names>C.W.</given-names>
</name>
<name>
<surname>Hedges</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Powell</surname>
<given-names>J.L.</given-names>
</name>
<name>
<surname>Aufderheide</surname>
<given-names>T.P.</given-names>
</name>
<name>
<surname>Rea</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Lowe</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Brown</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Dreyer</surname>
<given-names>J.</given-names>
</name>
<pub-id pub-id-type="pmid">18812533</pub-id>
</element-citation>
</ref>
<ref id="R7">
<label>7</label>
<element-citation publication-type="book">
<source/>Cardiac electrophysiology: from cell to bedside. 4-th ed. Philadelphia. WB Saunders, 2004. 1155 p.
          <year>2004</year>
<name>
<surname>Zipes</surname>
<given-names>D.P.</given-names>
</name>
<name>
<surname>Jalife</surname>
<given-names>J.</given-names>
</name>
</element-citation>
</ref>
<ref id="R8">
<label>8</label>
<element-citation publication-type="journal">
<source/>Annaly aritmologii. (In Russian).
          <year>2014</year>
<issue>3</issue>
<elocation-id></elocation-id>
<fpage>176</fpage>
<lpage>184</lpage>
<name>
<surname>Bockeria</surname>
<given-names>O.L.</given-names>
</name>
<name>
<surname>Akhobekov</surname>
<given-names>A.A.</given-names>
</name>
</element-citation>
</ref>
<ref id="R9">
<label>9</label>
<element-citation publication-type="journal">
<source/>Heart Rhythm. 2015. pii: S1547– 5271(15)00198-8.
          <elocation-id></elocation-id>
<name>
<surname>Schroder</surname>
<given-names>E.A.</given-names>
</name>
<name>
<surname>Burgess</surname>
<given-names>D.E.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Lefta</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Smith</surname>
<given-names>J.L.</given-names>
</name>
<name>
<surname>Patwardhan</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Bartos</surname>
<given-names>D.C.</given-names>
</name>
<name>
<surname>Elayi</surname>
<given-names>C.S.</given-names>
</name>
<name>
<surname>Esser</surname>
<given-names>K.A.</given-names>
</name>
<name>
<surname>Delisle</surname>
<given-names>B.P.</given-names>
</name>
</element-citation>
</ref>
<ref id="R10">
<label>10</label>
<element-citation publication-type="journal">
<source/>Circulation.
          <year>2009</year>
<volume>120</volume>
<issue>18</issue>
<fpage>1761</fpage>
<lpage>1767</lpage>
<name>
<surname>Schwartz</surname>
<given-names>P.J.</given-names>
</name>
<name>
<surname>Stramba-Badiale</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Crotti</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Pedrazzini</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Besana</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Bosi</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Gabbarini</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Goulene</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Insolia</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Mannarino</surname>
<given-names>S.</given-names>
</name>
<pub-id pub-id-type="pmid">19841298</pub-id>
</element-citation>
</ref>
<ref id="R11">
<label>11</label>
<element-citation publication-type="book">
<source/>Ventricular arrhythmias and sudden cardiac death. Clinical cardiology: diagnostic and treatment. – M.: Bakoulev Centre for cardiovasc surgery. 2011 (in Russian).
          <year>2011</year>
<fpage>598</fpage>
<name>
<surname>Bockeria</surname>
<given-names>AL.</given-names>
</name>
<name>
<surname>Golukhova</surname>
<given-names>EZ.</given-names>
</name>
</element-citation>
</ref>
<ref id="R12">
<label>12</label>
<element-citation publication-type="journal">
<source/>J. Am. Coll. Cardiol.
          <year>2013</year>
<volume>62</volume>
<issue>3</issue>
<elocation-id></elocation-id>
<fpage>169</fpage>
<lpage>180</lpage>
<name>
<surname>Schwartz</surname>
<given-names>P.J.</given-names>
</name>
<name>
<surname>Ackerman</surname>
<given-names>M.J.</given-names>
</name>
<name>
<surname>George</surname>
<given-names>Jr. A.L.</given-names>
</name>
<name>
<surname>Wilde</surname>
<given-names>A.</given-names>
</name>
<pub-id pub-id-type="pmid">23684683</pub-id>
</element-citation>
</ref>
<ref id="R13">
<label>13</label>
<element-citation publication-type="journal">
<source/>J. Clin. Invest.
          <year>2013</year>
<volume>123</volume>
<issue>1</issue>
<elocation-id></elocation-id>
<fpage>75</fpage>
<lpage>83</lpage>
<name>
<surname>Alfred</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>George</surname>
<given-names>Jr.</given-names>
</name>
<pub-id pub-id-type="pmid">23281413</pub-id>
</element-citation>
</ref>
<ref id="R14">
<label>14</label>
<element-citation publication-type="journal">
<source/>J. Cardiovasc. Electrophysiol.
          <year>2008</year>
<volume>19</volume>
<issue>12</issue>
<fpage>1289</fpage>
<lpage>1293</lpage>
<name>
<surname>Moss</surname>
<given-names>A.J.</given-names>
</name>
<name>
<surname>Zareba</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Schwarz</surname>
<given-names>K.Q.</given-names>
</name>
<name>
<surname>Rosero</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>McNitt</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Robinson</surname>
<given-names>J.L.</given-names>
</name>
<pub-id pub-id-type="pmid">18662191</pub-id>
</element-citation>
</ref>
<ref id="R15">
<label>15</label>
<element-citation publication-type="journal">
<source/>Pharmacol. Rev.
          <year>2010</year>
<volume>62</volume>
<issue>4</issue>
<fpage>760</fpage>
<lpage>781</lpage>
<name>
<surname>Kannankeril</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Roden</surname>
<given-names>D.M.</given-names>
</name>
<name>
<surname>Darbar</surname>
<given-names>D.</given-names>
</name>
<pub-id pub-id-type="pmid">21079043</pub-id>
</element-citation>
</ref>
<ref id="R16">
<label>16</label>
<element-citation publication-type="journal">
<source/>J. Intern. Med.
          <year>2006</year>
<volume>259</volume>
<issue>1</issue>
<fpage>59</fpage>
<lpage>69</lpage>
<name>
<surname>Roden</surname>
<given-names>D.M.</given-names>
</name>
<pub-id pub-id-type="pmid">16336514</pub-id>
</element-citation>
</ref>
<ref id="R17">
<label>17</label>
<element-citation publication-type="journal">
<source/>Heart Rhythm.
          <year>2012</year>
<volume>9</volume>
<issue>7</issue>
<fpage>1104</fpage>
<lpage>1112</lpage>
<name>
<surname>Crotti</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Hu</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Barajas-Martinez</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>De Ferrari</surname>
<given-names>G.M.</given-names>
</name>
<name>
<surname>Oliva</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Insolia</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Pollevick</surname>
<given-names>G.D.</given-names>
</name>
<name>
<surname>Dagradi</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Guerchicoff</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Greco</surname>
<given-names>F.</given-names>
</name>
<pub-id pub-id-type="pmid">22338672</pub-id>
</element-citation>
</ref>
<ref id="R18">
<label>18</label>
<element-citation publication-type="journal">
<source/>Annaly aritmologii.
          <year>2005</year>
<volume>4</volume>
<fpage>7</fpage>
<lpage>12</lpage>
<name>
<surname>Bockeria</surname>
<given-names>L. A.</given-names>
</name>
<name>
<surname>Revishvili</surname>
<given-names>A. Sh.</given-names>
</name>
<name>
<surname>Pronicheva</surname>
<given-names>I. V.</given-names>
</name>
</element-citation>
</ref>
<ref id="R19">
<label>19</label>
<element-citation publication-type="journal">
<source/>Circulation.
          <year>2011</year>
<volume>124</volume>
<fpage>2181</fpage>
<lpage>2184</lpage>
<name>
<surname>Schwartz</surname>
<given-names>P.J.</given-names>
</name>
<name>
<surname>Crotti</surname>
<given-names>L.</given-names>
</name>
<pub-id pub-id-type="pmid">22083145</pub-id>
</element-citation>
</ref>
<ref id="R20">
<label>20</label>
<element-citation publication-type="journal">
<source/>Circulation J.
          <year>2014</year>
<volume>78</volume>
<fpage>2827</fpage>
<lpage>2833</lpage>
<name>
<surname>Mizusawa</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Horie</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Wilde</surname>
<given-names>A.</given-names>
</name>
</element-citation>
</ref>
<ref id="R21">
<label>21</label>
<element-citation publication-type="journal">
<source/>Eur. Heart J.
          <year>2015</year>
<volume>36</volume>
<issue>41</issue>
<elocation-id></elocation-id>
<fpage>2793</fpage>
<lpage>2867</lpage>
<name>
<surname>Priori</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Blomstrom-Lunqvist</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Mazzanti</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Blom</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Borggrefe</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Camm</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Elliott</surname>
<given-names>P.M.</given-names>
</name>
<name>
<surname>Fitzsimons</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Hatala</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Hindricks</surname>
<given-names>G.</given-names>
</name>
<pub-id pub-id-type="pmid">26320108</pub-id>
</element-citation>
</ref>
<ref id="R22">
<label>22</label>
<element-citation publication-type="journal">
<source/>Curr. Probl. Cardiol.
          <year>2013</year>
<volume>38</volume>
<issue>10</issue>
<elocation-id></elocation-id>
<fpage>417</fpage>
<lpage>455</lpage>
<name>
<surname>Giudicessi</surname>
<given-names>J.R.</given-names>
</name>
<name>
<surname>Ackerman</surname>
<given-names>M.J.</given-names>
</name>
<pub-id pub-id-type="pmid">24093767</pub-id>
</element-citation>
</ref>
<ref id="R23">
<label>23</label>
<element-citation publication-type="journal">
<source/>Europace.
          <year>2013</year>
<volume>15</volume>
<fpage>1389</fpage>
<lpage>1406</lpage>
<name>
<surname>Priori</surname>
<given-names>S.G.</given-names>
</name>
<name>
<surname>Wilde</surname>
<given-names>A.A.</given-names>
</name>
<name>
<surname>Horie</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Cho</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Behr</surname>
<given-names>E.R.</given-names>
</name>
<name>
<surname>Berul</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Blom</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Brugada</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Chiang</surname>
<given-names>C.E.</given-names>
</name>
<name>
<surname>Huikuri</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Kannankeril</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Krahn</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Leenhardt</surname>
<given-names>A.</given-names>
</name>
<pub-id pub-id-type="pmid">23994779</pub-id>
</element-citation>
</ref>
<ref id="R24">
<label>24</label>
<element-citation publication-type="journal">
<source/>Circulation.
          <year>2004</year>
<volume>109</volume>
<fpage>1826</fpage>
<lpage>1833</lpage>
<name>
<surname>Schwartz</surname>
<given-names>P.J.</given-names>
</name>
<name>
<surname>Priori</surname>
<given-names>S.G.</given-names>
</name>
<name>
<surname>Cerrone</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Spazzolini</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Odero</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Napolitano</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Bloise</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>De Ferrari</surname>
<given-names>G.M.</given-names>
</name>
<name>
<surname>Klersy</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Moss</surname>
<given-names>A.J.</given-names>
</name>
<pub-id pub-id-type="pmid">15051644</pub-id>
</element-citation>
</ref>
<ref id="R25">
<label>25</label>
<element-citation publication-type="journal">
<source/>Circulation.
          <year>2010</year>
<volume>122</volume>
<fpage>1272</fpage>
<lpage>1282</lpage>
<name>
<surname>Schwartz</surname>
<given-names>P.J.</given-names>
</name>
<name>
<surname>Spazzolini</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Priori</surname>
<given-names>S.G.</given-names>
</name>
<name>
<surname>Crotti</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Vicentini</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Landolina</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Gasparini</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Wilde</surname>
<given-names>A.A.</given-names>
</name>
<name>
<surname>Knops</surname>
<given-names>R.E.</given-names>
</name>
<name>
<surname>Denjoy</surname>
<given-names>I.</given-names>
</name>
<pub-id pub-id-type="pmid">20837891</pub-id>
</element-citation>
</ref>
<ref id="R26">
<label>26</label>
<element-citation publication-type="journal">
<source/>Circ. Arrhythm. Electrophysiol.
          <year>2012</year>
<volume>5</volume>
<fpage>868</fpage>
<lpage>877</lpage>
<name>
<surname>Schwartz</surname>
<given-names>P.J.</given-names>
</name>
<name>
<surname>Crotti</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Insolia</surname>
<given-names>R.</given-names>
</name>
<pub-id pub-id-type="pmid">22895603</pub-id>
</element-citation>
</ref>
<ref id="R27">
<label>27</label>
<element-citation publication-type="journal">
<source/>Front. Physiol.
          <year>2013</year>
<volume>4</volume>
<part-title>166</part-title>
<elocation-id></elocation-id>
<fpage>1</fpage>
<lpage>16</lpage>
<name>
<surname>Adeniran</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Hancox</surname>
<given-names>J.C.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>H.</given-names>
</name>
<pub-id pub-id-type="pmid">23372552</pub-id>
</element-citation>
</ref>
<ref id="R28">
<label>28</label>
<element-citation publication-type="journal">
<source/>Indian Pacing Electrophysiol. J.
          <year>2010</year>
<volume>10</volume>
<issue>2</issue>
<fpage>86</fpage>
<lpage>95</lpage>
<name>
<surname>Crotti</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Taravelli</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Girardengo</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Schwartz</surname>
<given-names>P.</given-names>
</name>
<pub-id pub-id-type="pmid">20126594</pub-id>
</element-citation>
</ref>
<ref id="R29">
<label>29</label>
<element-citation publication-type="journal">
<source/>Front. Physiol.
          <year>2013</year>
<volume>15</volume>
<issue>4</issue>
<part-title>179</part-title>
<fpage>1</fpage>
<lpage>11</lpage>
<name>
<surname>Nielsen</surname>
<given-names>M.W.</given-names>
</name>
<name>
<surname>Holst</surname>
<given-names>A.G.</given-names>
</name>
<name>
<surname>Olesen</surname>
<given-names>S.P.</given-names>
</name>
<name>
<surname>Olesen</surname>
<given-names>M.S.</given-names>
</name>
</element-citation>
</ref>
<ref id="R30">
<label>30</label>
<element-citation publication-type="journal">
<source/>Methodist Debakey Cardiovasc. J.
          <year>2014</year>
<volume>10</volume>
<issue>1</issue>
<fpage>25</fpage>
<lpage>28</lpage>
<name>
<surname>Brugada</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Campuzano</surname>
<given-names>O.</given-names>
</name>
<name>
<surname>Sarquella-Brugada</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Brugada</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Brugada</surname>
<given-names>P.</given-names>
</name>
<pub-id pub-id-type="pmid">24932359</pub-id>
</element-citation>
</ref>
<ref id="R31">
<label>31</label>
<element-citation publication-type="journal">
<source/>Heart Rhythm.
          <year>2010</year>
<volume>7</volume>
<issue>1</issue>
<fpage>33</fpage>
<lpage>46</lpage>
<name>
<surname>Kapplinger</surname>
<given-names>J.D.</given-names>
</name>
<name>
<surname>Tester</surname>
<given-names>D.J.</given-names>
</name>
<name>
<surname>Alders</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Benito</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Berthet</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Brugada</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Brugada</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Fressart</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Guerchicoff</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Harris-Kerr</surname>
<given-names>C.</given-names>
</name>
<pub-id pub-id-type="pmid">20129283</pub-id>
</element-citation>
</ref>
<ref id="R32">
<label>32</label>
<element-citation publication-type="journal">
<source/>Circ. Res.
          <year>2001</year>
<volume>88</volume>
<fpage>E78</fpage>
<lpage>E83</lpage>
<name>
<surname>Baroudi</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Pouliot</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Denjoy</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Guicheney</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Shrier</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Chahine</surname>
<given-names>M.</given-names>
</name>
<pub-id pub-id-type="pmid">11420310</pub-id>
</element-citation>
</ref>
<ref id="R33">
<label>33</label>
<element-citation publication-type="journal">
<source/>Annaly aritmologii.
          <year>2010</year>
<volume>3</volume>
<fpage>16</fpage>
<lpage>30</lpage>
<name>
<surname>Bockeria</surname>
<given-names>L. A.</given-names>
</name>
<name>
<surname>Bockeria</surname>
<given-names>O. L.</given-names>
</name>
<name>
<surname>Kirtbaya</surname>
<given-names>L. N.</given-names>
</name>
</element-citation>
</ref>
<ref id="R34">
<label>34</label>
<element-citation publication-type="journal">
<source/>Circulation.
          <year>2001</year>
<volume>103</volume>
<fpage>485</fpage>
<lpage>490</lpage>
<name>
<surname>Laitinen</surname>
<given-names>P.J.</given-names>
</name>
<name>
<surname>Brown</surname>
<given-names>K.M.</given-names>
</name>
<name>
<surname>Piippo</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Swan</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Devaney</surname>
<given-names>J.M.</given-names>
</name>
<name>
<surname>Brahmbhatt</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Donarum</surname>
<given-names>E.A.</given-names>
</name>
<name>
<surname>Marino</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Tiso</surname>
<given-names>N.</given-names>
</name>
<pub-id pub-id-type="pmid">11157710</pub-id>
</element-citation>
</ref>
<ref id="R35">
<label>35</label>
<element-citation publication-type="journal">
<source/>Circulation.
          <year>2010</year>
<volume>121</volume>
<issue>5</issue>
<fpage>635</fpage>
<lpage>643</lpage>
<name>
<surname>Probst</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Veltmann</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Eckardt</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Meregalli</surname>
<given-names>P.G.</given-names>
</name>
<name>
<surname>Gaita</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Tan</surname>
<given-names>H.L.</given-names>
</name>
<name>
<surname>Babuty</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Sacher</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Giustetto</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Schulze-Bahr</surname>
<given-names>E.</given-names>
</name>
<pub-id pub-id-type="pmid">20100972</pub-id>
</element-citation>
</ref>
<ref id="R36">
<label>36</label>
<element-citation publication-type="journal">
<source/>Circulation.
          <year>2002</year>
<volume>105</volume>
<issue>1</issue>
<fpage>73</fpage>
<lpage>78</lpage>
<name>
<surname>Brugada</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Brugada</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Antzelevitch</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Towbin</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Nademanee</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Brugada</surname>
<given-names>P.</given-names>
</name>
<pub-id pub-id-type="pmid">11772879</pub-id>
</element-citation>
</ref>
<ref id="R37">
<label>37</label>
<element-citation publication-type="journal">
<source/>J. Saudi Heart Assoc.
          <year>2015</year>
<volume>27</volume>
<fpage>96</fpage>
<lpage>108</lpage>
<name>
<surname>Naseef</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Behr</surname>
<given-names>E.R.</given-names>
</name>
<name>
<surname>Batchvarov</surname>
<given-names>V.N.</given-names>
</name>
<pub-id pub-id-type="pmid">25870503</pub-id>
</element-citation>
</ref>
<ref id="R38">
<label>38</label>
<element-citation publication-type="journal">
<source/>J. Am. Coll. Cardiol.
          <year>2012</year>
<volume>59</volume>
<issue>1</issue>
<fpage>37</fpage>
<lpage>45</lpage>
<name>
<surname>Priori</surname>
<given-names>S.G.</given-names>
</name>
<name>
<surname>Gasparini</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Napolitano</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Della</surname>
<given-names>Bella P.</given-names>
</name>
<name>
<surname>Ottonelli</surname>
<given-names>A.G.</given-names>
</name>
<name>
<surname>Sassone</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Giordano</surname>
<given-names>U.</given-names>
</name>
<name>
<surname>Pappone</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Mascioli</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Rossetti</surname>
<given-names>G.</given-names>
</name>
<pub-id pub-id-type="pmid">22192666</pub-id>
</element-citation>
</ref>
<ref id="R39">
<label>39</label>
<element-citation publication-type="journal">
<source/>Am. J. Cardiol.
          <year>2015</year>
<volume>116</volume>
<issue>1</issue>
<elocation-id></elocation-id>
<fpage>98</fpage>
<lpage>103</lpage>
<name>
<surname>Letsas</surname>
<given-names>K.P.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Shao</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Korantzopoulos</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Giannopoulos</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Vlachos</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Georgopoulos</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Trikas</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Efremidis</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Deftereos</surname>
<given-names>S.</given-names>
</name>
<pub-id pub-id-type="pmid">25933735</pub-id>
</element-citation>
</ref>
<ref id="R40">
<label>40</label>
<element-citation publication-type="journal">
<source/>Circulation.
          <year>2002</year>
<volume>106</volume>
<fpage>69</fpage>
<lpage>74</lpage>
<name>
<surname>Priori</surname>
<given-names>S.G.</given-names>
</name>
<name>
<surname>Napolitano</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Memmi</surname>
<given-names>M.</given-names>
</name>
<pub-id pub-id-type="pmid">12093772</pub-id>
</element-citation>
</ref>
<ref id="R41">
<label>41</label>
<element-citation publication-type="journal">
<source/>Circ. Res.
          <year>2006</year>
<volume>99</volume>
<issue>3</issue>
<fpage>292</fpage>
<lpage>298</lpage>
<name>
<surname>Liu</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Colombi</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Memmi</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Zissimopoulos</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Rizzi</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Negri</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Imbriani</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Napolitano</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Lai</surname>
<given-names>F.A.</given-names>
</name>
<name>
<surname>Priori</surname>
<given-names>S.G.</given-names>
</name>
<pub-id pub-id-type="pmid">16825580</pub-id>
</element-citation>
</ref>
<ref id="R42">
<label>42</label>
<element-citation publication-type="journal">
<source/>Annaly aritmologii.
          <year>2005</year>
<issue>4</issue>
<fpage>30</fpage>
<lpage>35</lpage>
<name>
<surname>Bockeria</surname>
<given-names>E. L.</given-names>
</name>
</element-citation>
</ref>
<ref id="R43">
<label>43</label>
<element-citation publication-type="journal">
<source/>Annaly aritmologii.
          <year>2010</year>
<issue>4</issue>
<fpage>5</fpage>
<lpage>16</lpage>
<name>
<surname>Bockeria</surname>
<given-names>L. A.</given-names>
</name>
<name>
<surname>Bockeria</surname>
<given-names>O. L.</given-names>
</name>
<name>
<surname>Zavarina</surname>
<given-names>A. Yu.</given-names>
</name>
<name>
<surname>Kudzoeva</surname>
<given-names>Z.</given-names>
</name>
</element-citation>
</ref>
<ref id="R44">
<label>44</label>
<element-citation publication-type="journal">
<source/>Annaly aritmologii.
          <year>2009</year>
<volume>4</volume>
<fpage>7</fpage>
<lpage>20</lpage>
<name>
<surname>Bockeria</surname>
<given-names>L. A.</given-names>
</name>
<name>
<surname>Bockeria</surname>
<given-names>O. L.</given-names>
</name>
<name>
<surname>Kirtbaya</surname>
<given-names>L. N.</given-names>
</name>
</element-citation>
</ref>
<ref id="R45">
<label>45</label>
<element-citation publication-type="journal">
<source/>Eur. Heart J.
          <year>2015</year>
<volume>36</volume>
<issue>14</issue>
<elocation-id></elocation-id>
<fpage>847</fpage>
<lpage>885</lpage>
<name>
<surname>Bhonsale</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Groeneweg</surname>
<given-names>J.A.</given-names>
</name>
<name>
<surname>James</surname>
<given-names>C.A.</given-names>
</name>
<name>
<surname>Dooijes</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Tichnell</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Jongbloed</surname>
<given-names>J.D.</given-names>
</name>
<name>
<surname>Murray</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>te Riele</surname>
<given-names>A.S.</given-names>
</name>
<name>
<surname>van den Berg</surname>
<given-names>M.P.</given-names>
</name>
<name>
<surname>Bikker</surname>
<given-names>H.</given-names>
</name>
<pub-id pub-id-type="pmid">25616645</pub-id>
</element-citation>
</ref>
<ref id="R46">
<label>46</label>
<element-citation publication-type="journal">
<source/>Circ. J.
          <year>2015</year>
<volume>79</volume>
<issue>5</issue>
<elocation-id></elocation-id>
<fpage>901</fpage>
<lpage>913</lpage>
<name>
<surname>Calkins</surname>
<given-names>H.</given-names>
</name>
<pub-id pub-id-type="pmid">25877738</pub-id>
</element-citation>
</ref>
<ref id="R47">
<label>47</label>
<element-citation publication-type="journal">
<source/>Circulation.
          <year>2010</year>
<volume>31</volume>
<fpage>1533</fpage>
<lpage>1541</lpage>
<name>
<surname>Marcus</surname>
<given-names>F.I.</given-names>
</name>
<name>
<surname>McKenna</surname>
<given-names>W.J.</given-names>
</name>
<name>
<surname>Sherrill</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Basso</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Bauce</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Bluemke</surname>
<given-names>D.A.</given-names>
</name>
<name>
<surname>Calkins</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Corrado</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Cox</surname>
<given-names>M.G.</given-names>
</name>
<name>
<surname>Daubert</surname>
<given-names>J.P.</given-names>
</name>
<pub-id pub-id-type="pmid">20172911</pub-id>
</element-citation>
</ref>
<ref id="R48">
<label>48</label>
<element-citation publication-type="journal">
<source/>J. Am. Coll. Cardiol.
          <year>2011</year>
<volume>58</volume>
<fpage>1485</fpage>
<lpage>1496</lpage>
<name>
<surname>Bhonsale</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>James</surname>
<given-names>C.A.</given-names>
</name>
<name>
<surname>Tichnell</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Murray</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Gagarin</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Philips</surname>
<given-names>B.</given-names>
</name>
<pub-id pub-id-type="pmid">21939834</pub-id>
</element-citation>
</ref>
<ref id="R49">
<label>49</label>
<element-citation publication-type="journal">
<source/>Heart Rhythm.
          <year>2015</year>
<volume>12</volume>
<fpage>716</fpage>
<lpage>725</lpage>
<name>
<surname>Philips</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Te Riele</surname>
<given-names>A.S.</given-names>
</name>
<name>
<surname>Sawant</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Kareddy</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>James</surname>
<given-names>C.A.</given-names>
</name>
<name>
<surname>Murray</surname>
<given-names>B.</given-names>
</name>
<pub-id pub-id-type="pmid">25530221</pub-id>
</element-citation>
</ref>
<ref id="R50">
<label>50</label>
<element-citation publication-type="journal">
<source/>Europace.
          <year>2014</year>
<volume>16</volume>
<elocation-id></elocation-id>
<fpage>600</fpage>
<lpage>603</lpage>
<name>
<surname>Hocini</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Pison</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Proclemer</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Larsen</surname>
<given-names>T.B.</given-names>
</name>
<name>
<surname>Madrid</surname>
<given-names>A.</given-names>
</name>
<pub-id pub-id-type="pmid">24711616</pub-id>
</element-citation>
</ref>
</ref-list>
</back>
</article>
</pmc-articleset>